CN110234649A - Fgfr4抑制剂的盐、晶体、制备方法及其用途 - Google Patents
Fgfr4抑制剂的盐、晶体、制备方法及其用途 Download PDFInfo
- Publication number
- CN110234649A CN110234649A CN201880009211.8A CN201880009211A CN110234649A CN 110234649 A CN110234649 A CN 110234649A CN 201880009211 A CN201880009211 A CN 201880009211A CN 110234649 A CN110234649 A CN 110234649A
- Authority
- CN
- China
- Prior art keywords
- crystal form
- formula
- compound
- map
- follows
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
涉及FGFR4抑制剂的盐、晶体、制备方法及其用途。特别涉及式(I)化合物的可药用盐的晶型及其制备方法，以及含有治疗有效量的该晶型的药物组合物和其在治疗癌症中的用途。
Description
PCT国内申请，说明书已公开。
Claims (132)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017110478403 | 2017-10-31 | ||
| CN201711047840 | 2017-10-31 | ||
| PCT/CN2018/112891 WO2019085927A1 (zh) | 2017-10-31 | 2018-10-31 | Fgfr4抑制剂的盐、晶体、制备方法及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110234649A true CN110234649A (zh) | 2019-09-13 |
| CN110234649B CN110234649B (zh) | 2021-10-15 |
Family
ID=66333433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880009211.8A Active CN110234649B (zh) | 2017-10-31 | 2018-10-31 | Fgfr4抑制剂的盐、晶体、制备方法及其用途 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN110234649B (zh) |
| WO (1) | WO2019085927A1 (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105683188A (zh) * | 2013-10-25 | 2016-06-15 | 诺华股份有限公司 | 作为fgfr4抑制剂的稠环二环吡啶基衍生物 |
| WO2016151501A1 (en) * | 2015-03-25 | 2016-09-29 | Novartis Ag | Pharmaceutical combinations |
| WO2016151500A1 (en) * | 2015-03-25 | 2016-09-29 | Novartis Ag | Particles of n-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2- oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2h)-carboxamide |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109071532B (zh) * | 2016-05-20 | 2021-04-27 | 江苏豪森药业集团有限公司 | Fgfr4抑制剂、其制备方法和应用 |
-
2018
- 2018-10-31 WO PCT/CN2018/112891 patent/WO2019085927A1/zh active Application Filing
- 2018-10-31 CN CN201880009211.8A patent/CN110234649B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105683188A (zh) * | 2013-10-25 | 2016-06-15 | 诺华股份有限公司 | 作为fgfr4抑制剂的稠环二环吡啶基衍生物 |
| WO2016151501A1 (en) * | 2015-03-25 | 2016-09-29 | Novartis Ag | Pharmaceutical combinations |
| WO2016151500A1 (en) * | 2015-03-25 | 2016-09-29 | Novartis Ag | Particles of n-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2- oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2h)-carboxamide |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019085927A1 (zh) | 2019-05-09 |
| CN110234649B (zh) | 2021-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20210045998A (ko) | 헤테로사이클릭 스피로 화합물 및 암 치료를 위한 그의 사용 방법 | |
| CN102933574B (zh) | (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用 | |
| CN109071532A (zh) | Fgfr4抑制剂、其制备方法和应用 | |
| CA2981530A1 (en) | Substituted quinazoline compounds and methods of use thereof | |
| CN109232440A (zh) | 用于抑制激酶活性的二苯氨基嘧啶类化合物 | |
| CN109563091A (zh) | Fgfr4抑制剂及其制备方法和应用 | |
| Fan et al. | Discovery of Dioxino [2, 3-f] quinazoline derivative VEGFR-2 inhibitors exerting significant antipro-liferative activity in HUVECs and mice | |
| CN107619388A (zh) | 作为fgfr抑制剂的杂环化合物 | |
| CN103224496A (zh) | 三环类PI3K和/或mTOR抑制剂 | |
| Wei et al. | Synthesis and anti-tumor activity of [1, 4] dioxino [2, 3-f] quinazoline derivatives as dual inhibitors of c-Met and VEGFR-2 | |
| CN109745321A (zh) | 包含fgfr4抑制剂的药物组合物 | |
| CN101948467B (zh) | 噻唑酰胺类化合物及其在制备抗恶性肿瘤药物中的用途 | |
| CN108026046A (zh) | 取代的喹唑啉化合物及其作为g12c突变体kras、hras和/或nras蛋白质的抑制剂的用途 | |
| CN109456331A (zh) | 一种取代的吡唑并[1,5-a]嘧啶化合物及其药物组合物及用途 | |
| EP2740738B1 (en) | Platinum compounds for treating cell proliferative disease, preparation methods and uses thereof | |
| CN116133662A (zh) | 氮杂环丁烷取代化合物的晶型 | |
| CN103980287B (zh) | 含色酮腙结构的噻吩并嘧啶类化合物的制备及应用 | |
| CN105153190A (zh) | 含联芳基酰胺结构的杂环并嘧啶类化合物及其制备方法和应用 | |
| CN110467637B (zh) | 一种含有氧化膦类取代苯胺的双氨基氯代嘧啶类化合物、制备方法及其应用 | |
| CN110234649A (zh) | Fgfr4抑制剂的盐、晶体、制备方法及其用途 | |
| WO2022257965A1 (zh) | 固体形式的周期蛋白依赖性激酶9抑制剂及其用途 | |
| CN106866642B (zh) | 含芳基酰腙结构的喹唑啉类化合物及其应用 | |
| CN111675647B (zh) | 2-吲哚酮类pak1抑制剂及其在抗肿瘤治疗药物中的应用 | |
| US11465986B2 (en) | Crystal form of c-MET inhibitor and salt form thereof and preparation method therefor | |
| TWI788444B (zh) | Ｆｇｆｒ４抑制劑晶型及其製備方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40008546 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |